Home Current Issue Previous Issues Published Ahead-of-Print Collections For Authors Journal Info
Skip Navigation LinksHome > December 2006 - Volume 26 - Issue 6 > Priapism Associated With the Switch From Oral to Injectable...
You could be reading the full-text of this article now...
If you have access to this article through your institution, you can view this article in OvidSP.
Journal of Clinical Psychopharmacology:
December 2006 - Volume 26 - Issue 6 - pp 626-628
doi: 10.1097/01.jcp.0000239792.29449.3c
Brief Reports

Priapism Associated With the Switch From Oral to Injectable Risperidone

Kirshner, Alla MD, FRCPC; Davis, Robert R. RPN

Collapse Box

Abstract

Priapism is a rare, but serious, side effect of psychotropic medications. Psychotropic medication-induced priapism is believed to be caused by the α-adrenergic antagonism of these medications. Among the atypical antipsychotics, cases of priapism or prolonged erection have been associated with clozapine, olanzapine, risperidone, and quetiapine. Risperidone has primarily serotonergic, dopaminergic, and α-adrenergic antagonist properties. It has one of the highest affinities for the α1-adrenergic receptor blockade among the atypical antipsychotics. To date, there are 17 case reports of risperidone-associated priapism either in monotherapy or in combination with other psychotropics. To our knowledge, there are no published case reports of priapism on the injectable preparation of risperidone. We report a case of a 50-year-old man who developed priapism while being switched from the oral to the intramuscular preparation of risperidone. The importance of early recognition and intervention in cases of priapism is emphasized. The treatment of priapism with benztropine and other methods is discussed.

© 2006 Lippincott Williams & Wilkins, Inc.

Login




Help

Forgot Password?